JP2021512893A5 - - Google Patents

Info

Publication number
JP2021512893A5
JP2021512893A5 JP2020542546A JP2020542546A JP2021512893A5 JP 2021512893 A5 JP2021512893 A5 JP 2021512893A5 JP 2020542546 A JP2020542546 A JP 2020542546A JP 2020542546 A JP2020542546 A JP 2020542546A JP 2021512893 A5 JP2021512893 A5 JP 2021512893A5
Authority
JP
Japan
Prior art keywords
theta
degrees
approximately
polymorph
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542546A
Other languages
English (en)
Japanese (ja)
Other versions
JP7550646B2 (ja
JP2021512893A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017117 external-priority patent/WO2019157225A2/en
Publication of JP2021512893A publication Critical patent/JP2021512893A/ja
Publication of JP2021512893A5 publication Critical patent/JP2021512893A5/ja
Application granted granted Critical
Publication of JP7550646B2 publication Critical patent/JP7550646B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542546A 2018-02-08 2019-02-07 特定の化学物質、組成物、および方法 Active JP7550646B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628194P 2018-02-08 2018-02-08
US62/628,194 2018-02-08
PCT/US2019/017117 WO2019157225A2 (en) 2018-02-08 2019-02-07 Certain chemical entities, compositions, and methods

Publications (3)

Publication Number Publication Date
JP2021512893A JP2021512893A (ja) 2021-05-20
JP2021512893A5 true JP2021512893A5 (OSRAM) 2022-02-16
JP7550646B2 JP7550646B2 (ja) 2024-09-13

Family

ID=67549574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542546A Active JP7550646B2 (ja) 2018-02-08 2019-02-07 特定の化学物質、組成物、および方法

Country Status (12)

Country Link
US (1) US11465975B2 (OSRAM)
EP (1) EP3749310B1 (OSRAM)
JP (1) JP7550646B2 (OSRAM)
KR (1) KR20200143361A (OSRAM)
CN (1) CN112105365A (OSRAM)
AU (1) AU2019218893B2 (OSRAM)
CA (1) CA3090528A1 (OSRAM)
ES (1) ES3065300T3 (OSRAM)
IL (1) IL276476B2 (OSRAM)
PH (1) PH12020551193A1 (OSRAM)
SG (1) SG11202007492XA (OSRAM)
WO (1) WO2019157225A2 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255434A4 (en) * 2020-12-02 2024-10-23 Neupharma, Inc. CERTAIN CHEMICALS, COMPOSITIONS AND PROCESSES

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
MY161925A (en) 2011-07-27 2017-05-15 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
CN107245056A (zh) * 2011-08-26 2017-10-13 润新生物公司 化学实体、组合物及方法
MX362247B (es) * 2013-03-06 2019-01-09 Astrazeneca Ab Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico.
DK3035936T3 (da) * 2013-08-23 2019-06-11 Neupharma Inc Visse kemiske enheder, sammensætninger og fremgangsmåder
EP3395811B1 (en) * 2015-12-25 2020-05-13 Xuanzhu Pharma Co., Ltd. Crystals of quinazoline derivative and preparation method therefor

Similar Documents

Publication Publication Date Title
TWI619694B (zh) 用於製備喹啉衍生物之方法
TWI704142B (zh) 抗癌劑1-((4-(4-氟-2-甲基-1h-吲哚-5-基氧基)-6-甲氧基喹啉-7-基氧基)甲基)環丙胺的製備方法、及其藥物的結晶形及其鹽類
TWI417292B (zh) 2-甲基-2-〔4-(3-甲基-2酮-8-喹啉-3-基-2,3-二氫-咪唑并〔4,5-c〕喹啉-1-基)-苯基〕-丙腈之鹽及結晶型式
EP3248983B1 (en) Crystal form a of obeticholic acid and preparation method therefor
JP6170146B2 (ja) チロシンキナーゼ阻害剤二マレイン酸塩のi型結晶およびその製造法
TWI705060B (zh) 一種mek激酶抑制劑的對甲苯磺酸鹽、其結晶形式及製備方法
JP3665053B2 (ja) 純結晶形態の5−クロロ−3−(4−メタンスルホニルフェニル)−6’−メチル−[2,3’]ビピリジニルおよび合成方法
CA2588398A1 (en) Potassium salt of an hiv integrase inhibitor
EP1919893A2 (en) Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
KR102612379B1 (ko) 벤조푸란 유도체 자유 염기의 결정 및 제조 방법
WO2016165677A1 (en) New forms of ixazomib citrate
WO2018007927A1 (en) Process for preparation of palbociclib
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
US6521642B2 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
TW202024078A (zh) Bet溴結構域(bromodomain)抑制劑之固體形式之製備方法
WO2019037591A1 (zh) 盐酸美法仑晶型及其制备方法与应用
TW201625582A (zh) 製備吡蟲啉(imidacloprid)多晶型的方法
US20020147221A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
WO2023068253A1 (ja) ベンゾチオフェン化合物の新規結晶形及びその製造方法
US20110184067A1 (en) O-desmethylvenlafaxine succinate polymorph & process for preparing thereof
EP2019113A1 (en) New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one
EP1768969B1 (en) Crystalline mycophenolate sodium
CN115397426A (zh) 伊布替尼葡糖糖酸内酯共晶体及其制备方法
US9328115B2 (en) Process for preparing meropenem trihydrate
WO2019029477A1 (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法